Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The 5-year survival rate for all cancers diagnosed between 1995 and 2001 is up from 50% in 1974-1976 to 65%.  
  • A modest decrease of 1% in cancer mortality has been estimated to be worth $500 billion in social value.  
  • Chemotherapy drugs now target specific genomic abnormalities, about 150 effective drugs are available for cancer therapy, and new surgical techniques minimize negative consequences while producing better results.   
  • Percentage of women age 50 and over who had a mammogram in the past 2 years, by age group, selected years 1987-2005  
  • Medicines in Devlopment for Cancer, 2008